Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
PhoreMost
PhoreMost
Activities:
Research & Development
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
PhoreMost partners with Roche on multi-project drug target collab
PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER
Manufacturing
PhoreMost expands into Cambridge facility at Unity Campus
This relocation places the company in close proximity to numerous life science and technology organisations
Research & Development
NeoCura and PhoreMost announce collaboration on cancer therapeutics
As part of the collaboration, PhoreMost's Siteseeker phenotypic screening platform and NeoCura's full-process RNA drug design platform will be used
Pharmaceutical
PhoreMost fills Director roles with an OBE and a PhD
UK biopharma has appointed Dr Beech as a Non-Executive Director and Dr Cross as Senior Director of Technology
Drug Delivery
Boehringer chooses PhoreMost for new drug discovery collaboration
PhoreMost's Siteseeker platform will be deployed to identify novel targets for Boehringer’s programmes
Media
PhoreMost and o2h discovery collaborate
Collaboration will aim to progress first-in-class drug discovery programmes
Research & Development
Funding to support novel cancer immunotherapy programme
Award of the grant funds expanded operations and recognises innovative drug discovery programme
Subscribe now